Noninvasive Detection of AR-FL/AR-V7 as a Predictive Biomarker for Therapeutic Resistance in Men with Metastatic Castration-Resistant Prostate Cancer
Technical Report,30 Sep 2016,29 Sep 2017
Johns Hopkins University Baltimore United States
Pagination or Media Count:
Understanding primary and acquired resistance to abiraterone and enzalutamide, and developing analytically validated and clinically qualified predictive biomarkers, remains a critically important unmet medical need. We propose non-invasive detection of full-length androgen receptor AR-FL and the androgen receptor splice variant 7AR-V7 AR-FLAR-V7 as a predictive biomarker for therapeutic resistance in men with metastatic castration resistant prostate cancer.
- Medicine and Medical Research